Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Colorectal Neoplasms 43Stomach Neoplasms 42Rectal Neoplasms 28Pancreatic Neoplasms 16Lymphoma, Large B-Cell, Diffuse 13Colonic Neoplasms 13Cholangiocarcinoma 11Neoplasm Metastasis 10Adenocarcinoma 10Neoplasms 9Carcinoma, Hepatocellular 8Carcinoma, Non-Small-Cell Lung 7Biliary Tract Neoplasms 7Locally Advanced Rectal Cancer 6Gastrointestinal Neoplasms 6Gallbladder Neoplasms 6Esophageal Neoplasms 6Adenocarcinoma Of Esophagus 6Recurrence 5Peritoneal Neoplasms 5Ovarian Neoplasms 4Esophageal Squamous Cell Carcinoma 3Carcinoma 3Bile Duct Neoplasms 3Appendiceal Neoplasms 3Advanced Solid Tumors 3Advanced Solid Tumor 3Pathologic Complete Response 2Melanoma 2Lymphoma, Non-Hodgkin 2

Interventions

zaleplon 1olaparib 1Rehabilitation 1Psychotherapy 1Paclitaxel 1Oxaliplatin 1Olanzapine 1Nivolumab 1Niacin 1Injections 1Health Services Needs and Demand 1Gemcitabine 1Cisplatin 1Capecitabine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Advanced Cancer × Oxaliplatin × Clear all
NCT04495296 2025-12-19

A Trial to Evaluate Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of TST001 in Advanced or Metastatic Solid Tumors

Suzhou Transcenta Therapeutics Co., Ltd.

Phase 1/2 Recruiting
320 enrolled

Advanced Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡